Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics, Inc. (RNAC)
Company Research
Source: GlobeNewswire
FREDERICK, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On January 2, 2026, the Company issued to these employees options to purchase an aggregate of 7,350 shares of the Company’s common stock with an exercise price of $6.76, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The options vest as to 25% on January 2, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the options will be fully vested on January 2, 2030. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Na
Show less
Read more
Impact Snapshot
Event Time:
RNAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNAC alerts
High impacting Cartesian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RNAC
News
- Cartesian Therapeutics (NASDAQ:RNAC) had its price target raised by analysts at Needham & Company LLC from $40.00 to $42.00. They now have a "buy" rating on the stock.MarketBeat
- Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook [Yahoo! Finance]Yahoo! Finance
- Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 OutlookGlobeNewswire
- Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of DirectorsGlobeNewswire
RNAC
Earnings
- 11/6/25 - Miss
RNAC
Sec Filings
- 1/13/26 - Form 144
- 1/9/26 - Form 144
- 1/9/26 - Form 8-K
- RNAC's page on the SEC website